BRAF and melanoma: The role of effective systemic therapies such as PD-1 immune checkpoint blockade (ICB) immunotherapy and BRAF directed targeted therapy (TT) is now well established, both in unresectable stage III and metastatic stage IV (together also known as ‘advanced’) melanoma, as well as in the adjuvant treatment of stage III melanoma with a reduced risk of recurrence and improved distant metastasis-free survival [7–9].